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Background: Results of previous research have identified
the need for further investigation into the compliance
with good practice guidelines for current decision-
analytic modeling (DAM). Objective: To identify the
extent to which recent model-based economic evaluations
of interventions focused on lowering the blood pressure
(BP) of patients with hypertension conform to published
guidelines for DAM in health care using a five-dimension
framework developed to assess compliance to DAM
guidelines. Methods: A systematic review of English lan-
guage articles was undertaken to identify published
model-based economic evaluations that examined inter-
ventions aimed at lowering BP. The review covered the
period January 2000 to March 2015 and included the fol-
lowing electronic bibliographic databases: EMBASE and
Medline via Ovid interface and the Centre for Reviews
and Dissemination’s (CRD) NHS-EED. Data were
extracted based on different components of good practice
across five dimensions utilizing a framework to assess
compliance to DAM guidelines. Results: Thirteen articles
were included in this review. The review found limited
compliance to good practice DAM guidelines, which was
most frequently justified by the lack of data. Conclusions:
The assessment of structural uncertainty cannot yet be con-
sidered common practice in primary prevention and man-
agement of hypertension, and researchers seem to face
difficulties with identifying sources of structural uncertainty
and then handling them correctly. Additional guidelines
are needed to aid researchers in identifying and managing
sources of potential structural uncertainty. Adherence to
guidelines is not always possible and it does pose chal-
lenges, in particular when there are limitations due to data
availability that restrict, for example, a validation process.
Key words: decision-analytic modeling; modeling;
guidelines; good practice; cardiovascular disease. (MDM
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Cardiovascular disease (CVD), which incorpo-rates coronary heart disease (CHD) and stroke,
is the main cause of death worldwide1 and in
England and Wales.2 Hypertension, defined as a
persistent raised blood pressure (BP) of 140/90
mmHg,3 has been recognized as the most important
modifiable risk factor for CVD.2,3 Poorly controlled
high BP can damage artery walls and increase the
risk of developing a blood clot. Moreover, if it is
not treated it can also damage organs such as the
kidneys, heart, and brain. Decision-analytic model-
ing (DAM) guidelines have recognized that
randomized controlled clinical trials (RCTs) are
good sources of evidence to judge the effectiveness
of treatments; however, because the time horizon
for trials often does not reflect the full duration of
the impact of interventions, DAM is used to extend
the results of a short-term trial over a longer time
horizon.4,5 A primary outcome used in RCTs that
are focused on hypertension is often change in BP.
However, this is only an intermediate outcome, and
DAM can be used to examine the impact of change
in BP on the risk of CVD events in the longer term.
Previous research has identified the need for fur-
ther investigation into the compliance of DAM to
good practice and its impact on the conclusions
drawn from economic evaluations.6 Our aim is to
critically evaluate how DAM in primary prevention
of CVD conforms to guidelines and, in doing so,
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validate a framework previously developed to
assess compliance to guidelines. The focus here is
on one particular clinical area since this makes it
possible to remove some of the variation between
models that is not relevant for the purpose of asses-
sing compliance (e.g., different outcomes, treatment
options, or sources of uncertainty). CVD prevention
has been selected due to the wide number of recent
and available model-based cost-effectiveness stud-
ies conducted in this topic area. We focused on
interventions aimed at lowering BP, as a modifiable
risk factor for CVD, and sought to answer the fol-
lowing research question: ‘‘To what extent do
model-based economic evaluations of primary pre-
vention interventions aimed at lowering BP in
patients with hypertension or at risk of developing
hypertension conform to the published guidelines
for DAM?’’
METHODS
Studies of interventions aimed at lowering BP
were reviewed and the challenges faced when
applying DAM methods were identified and dis-
cussed. A systematic review was conducted, meet-
ing the UK Centre for Review and Dissemination
guidance and the Preferred Reporting Items for
Systematic Reviews and Meta-Analysis (PRISMA)
guidelines for reporting.7
The review followed a structured approach for
framing research questions: patient population (P),
intervention (I), the comparator group (C), outcome
(O), and the study design (S), or PICOS.7 Articles
published from January 2000 to March 2015 and
written in English were included in this review if
they met all of the following conditions:
 The target population was individuals presenting
with high BP or at risk of developing hypertension
 The intervention(s) aimed at lowering BP
 Management of hypertension, as a modifiable risk factor
for CVD, was part of a primary prevention strategy
(when studies also included secondary prevention, we
have concentrated on the results for primary prevention)
 The study was a model-based economic evaluation
This review excluded systematic reviews, guide-
lines, trials, protocols, and conference abstracts. In
addition, we also excluded studies where the
interventions
 Were aimed at screening BP
 Were part of a polypill strategy
 Measured nonadherence to treatment
 Were part of a secondary prevention and treatment
strategy
Searches were undertaken using terms identified
by expert clinical opinion and a list of synonyms
identified for each term that helped inform the final
search terms used in this review (‘‘cost effectiveness,’’
‘‘mathematical model,’’ ‘‘decision analysis,’’ ‘‘Markov
model,’’ ‘‘decision tree,’’ ‘‘economic evaluation,’’
‘‘hypertension,’’ and ‘‘lowering blood pressure’’). The
search was undertaken using truncations and wild-
cards, and all synonyms were subsequently combined
with appropriate medical subject heading terms
(MeSH) or subject terms using Boolean operators (see
Online Appendices 1 and 2).
The following databases were searched: EMBASE
and Medline via the Ovid interface, and the Centre for
Reviews and Dissemination’s (CRD) NHS Economic
Evaluation Database (NHS-EED). In addition, we manu-
ally examined the reference lists of the studies
included in this review. All articles identified by data-
base searching were exported into ENDNOTE-X7 and
duplicate references were removed.
Titles identified by the searches were screened
by reading the abstract; this activity was completed
by two reviewers (SJ and CP). Articles that appeared
to be relevant at this point were obtained and
screened against the inclusion and exclusion criteria
(CP); several articles appeared relevant on reading
the abstract but were subsequently excluded after
reading the full article.
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All studies were manually searched and data
were extracted by a single reviewer (CP); any
doubtful point(s) were checked with at least one
another reviewer.6 The extraction tool consisted of
a framework6 that synthesizes contemporary DAM
guidelines in a single checklist instrument; this
framework was developed to aid researchers asses-
sing adherence to guidelines. The tool aided the
retrieval and organization of information from
each study across five dimensions (see Online
Appendix 3):
1. Problem concept
2. Model concept
3. Synthesis of evidence
4. Analysis of uncertainty
5. Model transparency and validation
This approach ensured that the review did not miss
any information related to the model building pro-
cess. Data were extracted as free text and in the
form of a ‘‘yes/no’’ response.
RESULTS
The database search yielded 2607 studies; after
removing 27 duplicates, 2580 studies were left for
screening. A total of 2549 studies were excluded
because they did not consider a CVD-related inter-
vention, were not a model-based economic evalua-
tion, or were focused on screening (Figure 1).
Thirty-one full-text articles were assessed for elig-
ibility, of which 18 were rejected as a secondary
prevention strategy. Thirteen studies were included
in this review, none of which were identified
through other sources (Figure 1).
Only two of the studies included were published
prior to 2004. Thus, it can be seen that the majority
of studies (11/13) would have had access to DAM
guidelines at the time of their publication (e.g.,
Weinstein and others8 or Philips and others9).
Four studies evaluated programs for the clinical
prevention and treatment of hypertension10–13 and
nine evaluated antihypertensive drug treatments to
lower BP (Table 1).14–22 Ten studies were cost-
utility analyses (CUA) or combined both CUA and a
Figure 1 Flow chart using the PRISMA statement for the systematic review.
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cost-effectiveness analysis (CEA)10–12,15–17,19–22 while
three studies were CEA13,14,18 (Table 1). The interven-
tion target (risk factor) examined was high BP. The
remainder of this section describes the main findings.
Problem Concept and Model Concept
The decision problem and study objective(s)
were stated in all the studies (Table 2), and all eval-
uated CE from a health care payer perspective. The
target decision-maker audience was made explicit
in 10/13 studies as that of the health care payer,
that is, including only the health effects experi-
enced by patients receiving the intervention and
costs for the medical services required to provide
the intervention.23 For the remaining studies,10,14,19
the perspective was left implicit. Ekman and
others19 commented that the analysis was ‘‘in a
Swedish health care setting’’, while Stevanovic and
others14 were interested ‘‘in the Dutch setting’’ and
Gandjour and Stock10 focused on those ‘‘insured by
the German SHI,’’ where SHI refers to the German
Statutory Health Insurance.
For all studies, the target population was indi-
viduals with hypertension or at risk of developing
hypertension (Tables 1 and 2), frequently stratified
by gender, presence of hypertension, age groups,
and mean age. The target population was always
modeled as closed (reflecting members entering
only at the start of the analysis).
Despite all the studies sharing a common aim,
namely, primary prevention of CVD via lowering BP,
these economic models compared a wide range of
interventions and presented their results using out-
come measures such as QALYs,10–12,15–17,19–22 life
years gained (LYG),13,14,16,18,20,22 net health benefits
(NHB),18 net monetary benefits (NMB),17 and expected
value of perfect information (EVPI)17 (Table 1).
Side effects were modeled in only one study.15
Four studies10,11,14,22 acknowledged the lack of
adverse events as a limitation of their results due to
lack of data. Two studies argued that since ‘‘previ-
ous clinical trials found that first-line hypertensive
drugs do not have more side effects than placebo’’13
or they have ‘‘mild side effects,’’19 there was no
need to model adverse effects. Similarly another
study argued that fatal side effects would have been
already captured in the clinical trials via the mea-
sure of effectiveness.18
All the studies commented on the reasons for the
selection of their comparators, where their choice
of comparators seems to have been governed by the
scope of the study. Two studies acknowledged as a
limitation the exclusion of relevant comparator(s)
arguing that there may be more relevant com-
parators not included.19,21 Furthermore, the ‘‘do
nothing’’ option was considered in four of the
studies.10,14,18,19
All the studies used Markov models and
included a figure showing the model structure; in
one study,13 the structure of the Markov model
shown in the figure did not seem to reflect the
structure of the model described in the text. The
model structures accounted for both acute and
chronic health states. Five studies made explicit
reference to how the structure of their models was
defined either by using an existing generic model,18
being based on disease progression,10,11 or consist-
ing of health states designed to reflect the course
and history of CVD events.22 One study reported
that ‘‘health states in the Markov model are based
on cardiovascular events measured in the previ-
ously reported registry study.’’21 For the remaining
studies it was inferred that the model structure was
based on disease progression.
A lifetime time horizon was adopted in all but
two studies: of these, one used a 5-year15 time hori-
zon for a population aged 65 years while the
second used 20 years for a population aged 18 and
older.22 The 5-year time horizon was justified as
matching the 5-year time span given to social secu-
rity authorities in China for budget planning,15
while the 20-year time horizon was not discussed.22
Cycle length, though rarely justified in the studies,
was always 1 year. Only one study10 justified their
choice as most of the data used in their model
referred to a 1-year period.
Synthesis of Evidence
Patient heterogeneity was considered in most of
the studies; results were presented by age
cohorts10,12,14,15,18 and gender.10–12,14–16,18,19,21
Some studies added further analyses based on the
risk of CVD,10,12,17 scenarios of SBP reduction,14,19
smoking,14 and patient adherence.14,22 The risks of
secondary events were modeled in seven of the
studies, for example, the risk of a further stroke
after a first stroke.12–14,18–21 In some instances,
assumptions were acknowledged; for example, the
study by Stevanovic and others14 assumed the risk
of secondary events to be equal to the risk of a first
nonfatal CVD event. The authors acknowledged
that this would lead to an underestimation of the
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CVD risk, and so an increased risk of death in
patients experiencing nonfatal CVD events was
adopted.14 In Wisloff and others,18 secondary non-
fatal events were allowed, and a patient experien-
cing a secondary event was assumed to be in a
health state that was worse than the state they were
already in. For example, a patient with stroke
sequelae that experiences a myocardial infarction
(MI) will have the risk and costs associated with the
stroke sequelae and not those related to MI. Perman
and others13 utilized expert opinion in the assess-
ment of the risk of secondary events. Montgomery
and others,12 due to a lack of data, assumed that any
second cardiovascular event was fatal and acknowl-
edged this as a limitation. Some studies that did not
use separate states to model secondary events10,11,22
captured the increased mortality from secondary
events through the mortality rate of patients surviv-
ing CVD events. Few of the studies acknowledged
the lack of epidemiological data to model secondary
events as a limitation.11,22
All studies applied discounting to their results: a
discount rate of 3% was most common for costs and
benefits;10,15,17,19,21,22 two studies used a different
discount rate for costs and benefits (Stevanovic and
others14 used 4% and 1.5%, while Montgomery and
others12 used 6% and 1.5%, respectively; Table 1).
Information on the parameters used as inputs were
most frequently presented in tables showing mean
values and the type of distribution(s) while some
studies also included 95% confidence intervals or
range intervals.10,11,20 The methods used to report
the sources of information varied from reporting a
detailed list of sources per parameter in a table to
mentioning the sources of data in the main text.
Analysis of Uncertainty
The studies examined and reported uncertainty
surrounding their identified outcomes through sen-
sitivity analysis (SA). Uncertainty in parameter esti-
mates was most commonly handled through
deterministic sensitivity analysis (DSA) and prob-
abilistic sensitivity analysis (PSA). Five studies
used only one-way DSA,12,15,19,20,22 while another
four11,16–18 only used PSA. Only one study mea-
sured EVPI17 (Table 2).
Elements pertaining to structural uncertainty
(SU) were acknowledged as such in six stud-
ies.10,11,13,14,19,20 Most commonly SU was assessed
through SA by varying the time horizon,11 the dura-
tion of the effectiveness of the treatment,11,14 the
discount rate,13,19 or by using alternative measures
of outcomes.19 One study examined the impact of
assumptions related to secondary events.18 Lack of
clinical evidence for key parameters such as the
treatment effect of drugs10,11,14 was identified as a
source of SU. Two studies acknowledged that they
could have included more relevant comparators
had they had more information,19,21 and another
two acknowledged that they had excluded a poten-
tially relevant state due to lack of epidemiological
data10 or insufficient evidence on its relevance.20
The decision about which events and health
states were included was partially discussed. Some
studies acknowledged that they subdivided a health
state11 (CHD into MI, HF, and angina), or excluded a
potentially relevant health state15 (combined stroke
and MI event). All studies included chronic health
states (post events); however, few discussed having
modeled the progression of disease.10,11,22 Most fre-
quently, the studies acknowledged the adoption of
assumptions, that is, assuming the duration of treat-
ment effects to be lifetime or as long as the time hori-
zon in the model,10,11,14 or 5 years19 or varied.21
Model Transparency and Validation
All the studies included a graphical description
of the Markov model they used (Table 2). Sources
of funding were identified in 11 studies: five were
funded by the pharmaceutical industry,14–16,19,21,22
one benefited from joint funds from government
and pharmaceutical sources,18 three were exclu-
sively government-funded,11,12,20 and one was pri-
vately funded.17 None of the studies stated any
means for accessing more detailed information
about the model. All the studies had a clear policy
context with an explicit statement of funder and
developer.
Validation, according to guidelines,24 is a set of
methods for judging the accuracy of a model in
making relevant predictions; in other words, valida-
tion helps readers understand what a model does
and how it does it. In this review, we checked for
five main types of validation. All the studies were
subjected to face validity checks (having been peer
reviewed and published in a journal) and they were
subjected to verification (internal validity check-
ing). The methods used were justified to a greater
or lesser extent in each study. All studies under-
took SA of parameters as a way to double check
that the direction and magnitude of their outputs
were as expected.
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In terms of cross-validation, results were mixed.
Eight studies10–14,17,19,20 examined different models
that addressed the same problem and compared
their results; however, the level of detail provided
varied. Five studies presented limited or no evi-
dence of cross-validation;15,16,18,21,22 only Wisloff
and others18 undertook an exercise of external vali-
dation by comparing their estimated lifetimes to
those reported by Statistics Norway and in doing so
they found that the input into their model needed
to be adjusted to fit Norwegian mortality data. An
assessment of predictive validity was not included
in any of the studies considered.
DISCUSSION
Using a previously developed practical frame-
work,6 we have critically evaluated how 13 pub-
lished economic evaluations conformed to
contemporaneous good practice guidelines. We
found that published economic evaluations of inter-
ventions aimed at lowering BP in patients with
hypertension, as part of a primary prevention strat-
egy of CVD, demonstrated limited compliance to
DAM guidelines, which has usually been explained
by lack of data or imperfect data. This was particu-
larly apparent in the assessment of SU (or lack of)
and model external validation.
This review identified common grounds in terms
of the adherence to, and use of, guidelines. The
conceptual modeling in all the studies included in
this review was based on a disease process where
the focus was on the definition of the health states
(conditions) as opposed to treatment (pathways)
received and where the decision problem posed
required the evaluation of the reduction in the risk
of developing hypertension, thus explaining the
use of Markov models.
It has been argued that alternative model struc-
tures can lead to variations in model predictions,25
most importantly, in the context of a primary pre-
vention strategy, an inappropriate model structure
may lead to poorly informed policy decisions,
resulting in inefficient allocation of scarce
resources.26 Models are by nature sensitive to
choices made at every single stage during the
model development process (i.e., model concept,
model structure). There will almost always be more
than one set of choices, and for this reason, guide-
lines have suggested assessing the extent to which
model predictions are influenced by the choices
made during the model development process and
have suggested methods to do so, such as scenario
analyses.27,28
Lifetime time horizons should be adopted (or be
justified when constrained by the cohort’s lifetime),
or at the very least, time horizons should be ‘‘long
enough’’ to capture relevant differences in out-
comes across strategies.23 Lack of data or imperfect
data still poses important challenges for research-
ers, for example, when modeling the risk of second-
ary events and disease progression or to attempt the
assessment of model validity. Even though ele-
ments pertaining to SU were identified by various
authors, the assessment of SU cannot be considered
common practice in this particular clinical area and
additional guidelines are still needed to aid
researchers identifying and quantifying SU.
External validity still poses a challenge to
researchers and, more importantly, to future guide-
lines due to the apparent unavailability of actual
extra data (from RCT or patient-level data) to under-
take the exercise. It has been suggested that instead
of using all the data available to create a model,
some data be set aside to use during the validation
process (e.g., one third of the data).29 This may or
may not always be possible, and will depend on
how much data a researcher has to build a model.
Studies included in this review shared similar
research questions and yet there was a great diver-
sity in the structures of the Markov models used.
Some of these were simple and some more com-
plex, and they were generally developed with lim-
ited justification.26 These indicate, as suggested by
Squires and other,30 that the methods for the devel-
opment of the model structure are still underdeve-
loped. This can lead to errors including poor
validity, credibility, and no basis for model verifica-
tion and the analysis of structural uncertainty.
Caro and Mo¨ller29 described the above as the dis-
posable approach to modeling: models are built for
a single use, focused on a particular product for a
relatively short time. This explains—to some
extent—the reduced motivation for undertaking
model validation.29 Future research should exam-
ine whether the development of ‘‘generic models,’’
or as proposed by Caro and Mo¨ller, the develop-
ment of multi-use models over time, can capture
sufficient detail to be realistic and avoid particulars
for which there are no data, and thereby allow the
economic evaluation of interventions targeting CVD
in any setting, and whether this will bridge the
knowledge gap and, most importantly, allow ease
of comparison between the results obtained from
different studies.
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This is the first study that has critically reviewed
compliance to DAM guidelines using a previously
developed practical framework. It has covered more
than a decade of published DAM studies of inter-
ventions aimed at lowering BP in patients with
hypertension. We believe the inclusion of recent
studies from European, American, and Asian coun-
tries has helped reflect current practice worldwide.
The exclusion criteria adopted may be consid-
ered as limitation; however, these were required to
guarantee consistency in the analysis. Furthermore,
a negligible number of non-English-language stud-
ies were identified pertaining to applied studies.
The fact that none of the studies included was pub-
lished after the release of the ‘‘five-dimension
framework’’ and the selection of one particular clin-
ical area (and any impact on generalizability this
may have) may also be considered a limitation.
Our findings seem in line with recent debate
around the methodological challenges being faced
by DAM where model validation and SU have been
identified as fundamental problems due to the lack
of motivation, time, and data to validate models
and, in the case of SU, a lack of methods.29
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